Diagnostic value of retrospectively fused 64CuCl2 PET/MRI in biochemical relapse of prostate cancer: comparison with fused 18F-Choline PET/MRI, 64CuCl2 PET/CT, 18F-Choline PET/CT, and mpMRI

被引:9
|
作者
Paparo, Francesco [1 ]
Peirano, Alice [2 ]
Matos, Joao [2 ]
Bacigalupo, Lorenzo [1 ]
Rossi, Umberto [3 ]
Mussetto, Ilaria [1 ]
Bottoni, Gianluca [4 ]
Ugolini, Martina [5 ]
Introini, Carlo [6 ]
Ruggieri, Filippo Grillo [7 ]
Rollandi, Gian Andrea [1 ]
Piccardo, Arnoldo [4 ]
机构
[1] EO Galliera Hosp, Dept Diagnost Imaging, Unit Radiol, Genoa, Italy
[2] Univ Genoa, Dept Hlth Sci, DISSAL, Via Antonio Pastore 1, I-16132 Genoa, GE, Italy
[3] EO Galliera Hosp, Dept Diagnost Imaging, Unit Intervent Radiol, Genoa, Italy
[4] EO Galliera Hosp, Dept Diagnost Imaging, Unit Nucl Med, Genoa, Italy
[5] EO Galliera Hosp, Dept Diagnost Imaging, Med Phys Unit, Genoa, Italy
[6] EO Galliera Hosp, Dept Urol, Prostate Unit, Genoa, Italy
[7] EO Galliera Hosp, Dept Diagnost Imaging, Unit Radiotherapy, Genoa, Italy
关键词
Prostate; Cancer; Recurrence; PET; Magnetic resonance imaging; RECURRENCE;
D O I
10.1007/s00261-020-02591-7
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Purpose To assess the diagnostic value of retrospectively fused PET/MRI by comparing the detection rates (DRs) of fused (CuCl2)-Cu-64 PET/MRI vs. fused F-18-Choline PET/MRI in patients with suspected prostatic cancer (PCa) recurrence. The secondary objective was to compare the DRs of fused PET/MRI vs. those of the separate imaging modalities. Methods We retrospectively evaluated 50 PCa patients with biochemical relapse after radical prostatectomy (RP) or radiotherapy (RT). All patients underwent (CuCl2)-Cu-64 PET/CT, F-18-Choline PET/CT, and multiparametric magnetic resonance imaging (mpMRI) within 15 days. Fused (CuCl2)-Cu-64-PET/MRI and fused F-18-Choline PET/MRI images were obtained by retrospective co-registration of MRI and PET images. Experienced readers interpreted the images, and the DRs of each imaging modality were assessed. Results In the patient-based analysis, overall DRs of fused (CuCl2)-Cu-64 PET/MRI, fused F-18-Choline PET/MRI, (CuCl2)-Cu-64 PET/CT, F-18-Choline PET/CT, and mpMRI were 88%, 68%, 82%, 56%, and 74%, respectively. In the lesion-based analysis, overall DRs of fused (CuCl2)-Cu-64 PET/MRI, fused F-18-Choline PET/MRI, (CuCl2)-Cu-64 PET/CT, (18) F-Choline PET/CT, and mpMRI were 95%, 66%, 87%, 58%, and 71%, respectively. Conclusions Retrospectively fused PET/MRI is able to overcome the limitations of the separate interpretation of the individual imaging modalities. Fused (CuCl2)-Cu-64 PET/MRI provided the highest diagnostic performance in the detection of PCa local relapse.
引用
收藏
页码:3896 / 3906
页数:11
相关论文
共 50 条
  • [31] 18F-Choline PET/CT Identifies High-Grade Prostate Cancer Lesions Expressing Bone Biomarkers
    Urbano, Nicoletta
    Scimeca, Manuel
    Crocco, Antonio
    Mauriello, Alessandro
    Bonanno, Elena
    Schillaci, Orazio
    JOURNAL OF CLINICAL MEDICINE, 2019, 8 (10)
  • [32] 18F-Choline PET/mpMRI for Detection of Clinically Significant Prostate Cancer: Part 2. Cost-Effectiveness Analysis
    Barnett, Christine L.
    Davenport, Matthew S.
    Montgomery, Jeffrey S.
    Kunju, Lakshmi Priya
    Denton, Brian T.
    Piert, Morand
    JOURNAL OF NUCLEAR MEDICINE, 2019, 60 (12) : 1705 - 1712
  • [33] Asymptomatic metastasis to cricoid from prostate carcinoma: an incidental finding detected on 18F-choline PET/CT
    Ng, Sheldon Jin Keat
    Sinha, Arvind Kumar
    Loi, Hoi Yin
    Khor, Lih Kin
    JAPANESE JOURNAL OF RADIOLOGY, 2015, 33 (05) : 298 - 301
  • [34] Optimized Protocol for 18F-Choline PET/CT in Patients with Biochemically Relapsed Prostate Cancer Experiences on 250 Consecutive Cases
    Chondrogiannis, Sotirios
    Marzola, Maria Cristina
    Grassetto, Gaia
    Rampin, Lucia
    Massaro, Arianna
    Colletti, Patrick M.
    Rubello, Domenico
    CLINICAL NUCLEAR MEDICINE, 2015, 40 (06) : E308 - E312
  • [35] An Incidental Pancreatic Finding at 18F-Choline PET/CT: Chronic Mass-Forming Pancreatitis
    Evangelista, Laura
    De Pellegrin, Alessandro
    Girometti, Rossano
    Cassarino, Gianluca
    Giacomuzzi, Francesco
    Rensi, Marco
    DIAGNOSTICS, 2021, 11 (08)
  • [36] Needle track recurrence after transrectal prostate biopsy detected by 18F-Choline PET-CT
    Garcia-Bennett, J.
    Henriquez, I.
    Zugazaga Cortazar, A.
    Fuertes, J.
    REVISTA ESPANOLA DE MEDICINA NUCLEAR E IMAGEN MOLECULAR, 2015, 34 (02): : 128 - 129
  • [37] The value of 18F-Choline PET/CT in patients with elevated PSA-level and negative prostate needle biopsy for localisation of prostate cancer
    Igerc, I.
    Kohlfuerst, S.
    Gallowitsch, H. J.
    Matschnig, S.
    Kresnik, E.
    Gomez-Segovia, I.
    Lind, P.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2008, 35 (05) : 976 - 983
  • [38] Resection of a Solitary Pulmonary Metastasis from Prostatic Adenocarcinoma Misdiagnosed as a Bronchocele Usefulness of 18F-Choline and 18F-FDG PET/CT
    Calais, Jeremie
    Lussato, David
    Menard, Jean
    De Kerviler, Eric
    Mongiat-Artus, Pierre
    Castier, Yves
    Merlet, Pascal
    JOURNAL OF THORACIC ONCOLOGY, 2014, 9 (12) : 1826 - 1829
  • [39] Comparison of PET imaging with a 68Ga-labelled PSMA ligand versus 18F-choline PET/CT for the diagnosis of Prostate Cancer & Radioprotection for involved personnel
    Khansa, Zeinab
    Haidar, Mohamad B.
    Neaimeh, Nemer
    Korek, Mahmoud
    HEALTH AND TECHNOLOGY, 2019, 9 (04) : 607 - 613
  • [40] 68Ga-PSMA-PET/CT in Patients With Biochemical Prostate Cancer Recurrence and Negative 18F-Choline-PET/CT
    Bluemel, Christina
    Krebs, Markus
    Polat, Buelent
    Linke, Fraenze
    Eiber, Matthias
    Samnick, Samuel
    Lapa, Constantin
    Lassmann, Michael
    Riedmiller, Hubertus
    Czernin, Johannes
    Rubello, Domenico
    Bley, Thorsten
    Kropf, Saskia
    Wester, Hans-Juergen
    Buck, Andreas K.
    Herrmann, Ken
    CLINICAL NUCLEAR MEDICINE, 2016, 41 (07) : 515 - 521